All News

The 2 analyses of data on fertility and infant mortality were conducted in the first 14 states to impose complete or 6-week bans after the Dobbs decision in June 2022.

Your daily dose of the clinical news you may have missed.

The 2025 Winter Clinical Hawaii kicks off today with the first full day of educational sessions starting tomorrow, February 15 - here's what to look for.

The development comes at a time when cannabis use disorder has risen steadily in the United States.

The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.

Your daily dose of the clinical news you may have missed.

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.

AAAAI 2025. Treatment response rates with daily use of the VIASKIN peanut patch increased from 39% at baseline to 73.3% at 60 months in youth aged 4 to 11 years.

Your daily dose of the clinical news you may have missed.

Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.

CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from a pilot study in T2D.

Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.

Your daily dose of the clinical news you may have missed.

Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.

The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.